Press Release

Recipharm makes
strategic investment in Synthonics and partners in development of novel compounds

Recipharm today announces that it has made an equity investment in Synthonics Inc and purchased $2.0 million of preferred stock in the company. A further $2.0 million of preferred stock will be purchased upon Synthonics' achievement of certain milestones, which could be expected during 2016. In addition, Synthonics and Recipharm have entered into a Joint Development Agreement under which Synthonics gains access to Recipharm's expertise in drug development, marketing and manufacturing in exchange for a royalty payment on certain of Synthonics' compounds

Read More

Welcome to Synthonics

We are a specialty pharmaceutical company focused on the discovery, development and licensing of drugs that incorporate our proprietary metal coordination chemistry. Metal coordination entails attaching a pharmaceutically acceptable metal, such as zinc, bismuth or magnesium, to a known pharmaceutical agent to create a new and more effective drug. The addition of the metal changes the way the drug is absorbed or delivered without altering the action of the underlying drug.

Metal coordination offers tremendous flexibility, allowing us to "dial in" the desired pharmacokinetics by varying the metals used and the manner in which they are attached. In its simplest application, metal coordination improves a drug's absorption and delivery without changing the way the drug works once delivered. Metal coordination can also be used to extend or control a drug’s release or to prevent a drug's systemic absorption.

Unlike salts, metal coordinated pharmaceuticals are generally patentable as new compositions of matter under U.S. patent laws--even if the parent drug is already well known. We hold four U.S. patents and have dozens of additional claims pending.

Metal coordination is a platform technology with broad application that can be profitably applied both to already marketed drugs and to drugs under development. We have drug discovery and development programs underway on a handful of molecules. In addition, we partner with large pharmaceutical companies to enhance their pipeline and marketed products.

Synthonics, Inc.     2200 Kraft Drive, Suite 2225      Blacksburg, VA 24060     Phone (540) 443-3645